BioSpace News Archive

Nabriva Therapeutics plc announced it has pivoted its strategic focus towards commercialization efforts, primarily focused on SIVEXTRO, to extend its cash runway, while exploring strategic options.

Jasper Therapeutics, Inc., a biotechnology company focused on developing multiple new therapies for the field of stem and cellular medicine, announced third quarter 2022 financial results and provided a corporate update.

CytoImmune Therapeutics today announced new preclinical data highlighting the potential of the company’s tumor-reactive NK (TRACK-NK) cell program, CYTO-102, to potently and selectively kill tumor cells with the mechanism of action of antibody-dependent cellular cytotoxicity.

Biostrap, a high-resolution biosensor-based digital biomarker platform pioneering the space of clinically reliable biosensors, data processing techniques and remote physiological monitoring, is soon to be releasing Ethos, a groundbreaking wearable technology to unlock the power of continuous raw photoplethysmography (PPG) data in health care research and patient care.

Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics company seeking to improve the outcomes, cost, and efficiency of surgical procedures, today announced their robotic system has been named one of TIME’s Best Inventions of 2022.

Visionable, a real-time clinical collaboration platform enabling virtual healthcare models, and Brainomix, an AI-powered medtech solutions company, have announced a powerful strategic partnership that is transforming the delivery of stroke care.

YS Biopharma Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for PIKA COVID-19 vaccine.

Enavate Sciences , a portfolio company of Patient Square Capital, is pleased to announce that H. Edward (Edd) Fleming, Jr , M.D. has joined the firm as Executive Vice President, Commercialization.

invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today presented data from the ongoing clinical trial of its APN401 cell therapy at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022) in Boston, MA.

In recognition of Veterans Day, the Prostate Cancer Foundation announces the extension of its Veterans Health Initiative to reach more Veterans with two new philanthropic precision oncology pilot programs at VA Medical Centers in Baltimore, MD, and Atlanta, GA.